Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmunityBio Inc. is conducting a Phase IIb clinical trial, officially titled QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors. The study aims to evaluate the efficacy of combination immunotherapies in patients with advanced solid tumors who have not responded to previous PD-1/PD-L1 therapies. This research is significant as it explores new treatment avenues for patients with limited options.
The study tests various combinations of the drug N-803 with other immunotherapies like pembrolizumab, nivolumab, and docetaxel, among others. These combinations are designed to enhance the immune response in patients who have developed resistance to standard checkpoint inhibitors.
The trial is non-randomized with a parallel intervention model, focusing on treatment as its primary purpose. There is no masking involved, meaning both researchers and participants know which treatments are being administered.
The study began on December 11, 2018, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 30, 2025, indicating ongoing recruitment and data collection.
This update could positively influence ImmunityBio’s stock performance by showcasing progress in developing innovative cancer treatments. Investors may view this as a promising step in the competitive oncology market, potentially boosting confidence in the company’s future prospects.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.